



# Signalife

Clear Data. Trusted Results.

Signalife, Inc.  
531 South Main St. ~ Suite 301  
Greenville, SC 29601  
T 864.233.2300  
F 864.233.2100  
[www.signalife.com](http://www.signalife.com)  
[info@signalife.com](mailto:info@signalife.com)

## PRESS RELEASE

Tuesday January 31, 2006 | 9:46 am ET

### Signalife, Inc. to Present At Brean Murray, Carret & Co. Small Cap Investor Conference

NEW YORK, Jan. 31 /PRNewswire-FirstCall/--Signalife, Inc. (Amex: SGN - News) creator of the advanced ambulatory ECG/EKG monitoring technology announced today that Pamela Bunes, President and CEO, has been invited to present at the Brean Murray, Carret & Co. Small Cap Investor Conference.

WHEN: February 1, 2006  
TIME: 2:30 PM  
WHERE: The Grand Hyatt, New York, NY  
WHO: Pamela Bunes, President and CEO

#### About Brean Murray, Carret & Co., LLC

Brean Murray, Carret & Co. is a full service institutional research, investment banking, and asset management firm with \$3 billion in combined assets under management, including its affiliates. It specializes in small and mid-capitalization companies. For more information, the company's website is available at: [www.breanmurraycarret.com](http://www.breanmurraycarret.com).

#### About Signalife

Signalife, Inc. is a medical device company focused on the monitoring and detection of cardiovascular disease through continuous ECG/EKG signal monitoring. The company's goal is to become the premier global provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that can simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife's revolutionary, FDA -approved patented ECG monitoring system called Fidelity 100 allows for the recording of a high-quality ECG signal from ambulatory cardiac patients. This means for the first time physicians will have immediate access to clinical real-time vital heart information. The Fidelity 100 will address a portion of the \$400 billion cardiovascular disease market which continues to grow. The company is traded on the American Stock Exchange under the symbol SGN. The website for the company is <http://www.signalife.com>.

#### Caution Regarding Forward-Looking Statements

Statements   
unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure   
ability to obtain   
in the value of Signalife's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission

###